The Latest Breaking News from AMGN

The biotech industry strengthened over the pandemic by drug and vaccine development initiatives to combat COVID-19. Moreover, significant government investments should bode well for this industry. Therefore, quality biotech stocks Amgen (AMGN) and Gilead Sciences (GILD) could be ideal buys in November. However, fundamentally weak stock Ginkgo Bioworks (DNA) might…

Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Stocks registered their biggest rally since 2020 yesterday, driven by the October inflation report that showed cooling price pressures. Moreover, the latest job report is raising hopes of a slower pace of rate hikes by the Fed. Therefore, we think it could be the right time for investors to buy…

After a series of consecutive aggressive rate hikes, the labor market shows some signs of cooling. Consequently, the Fed is expected to lower its hike pace. Moreover, as investors look forward to the midterm elections, fundamentally sound stocks Amgen (AMGN), Fortinet (FTNT), and BJ's Wholesale Club (BJ) might be ideal…

2022 has been a challenging year for investors due to the combination of inflation and a slowing economy. Biotech stocks could be a place where investors can find outperformance given their low valuations and strong long-term fundamentals. Amgen (AMGN), Corcept Therapeutics (CORT), and Regneron (REGN) are 3 to consider.

Someone with a lot of money to spend has taken a bullish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….

The biotech industry continues to stay resilient to broader economic challenges. Moreover, the planned multi-million-dollar government investments should bode well for the industry. Hence, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys to cash in on the industry’s prospects. However, fundamentally weak stock…